• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace Home
  • Enstitüler
  • Kanser Enstitüsü
  • Kanser Enstitüsü Makale Koleksiyonu
  • View Item
  •   DSpace Home
  • Enstitüler
  • Kanser Enstitüsü
  • Kanser Enstitüsü Makale Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Targeted Therapies in Gastric Cancer and Future Perspectives

View/Open
licence.txt (242bytes)
WJG-22-471 (1).pdf (1.414Mb)
Date
2016
Author
Yazıcı, Ozan
Şendur, M. Ali Nahit
Özdemir, Nuriye
Aksoy, Sercan
xmlui.mirage2.itemSummaryView.MetaData
Show full item record
Abstract
Advanced gastric cancer (AGC) is associated with a high mortality rate and, despite multiple new chemotherapy options, the survival rates of patients with AGC remains poor. After the discovery of targeted therapies, research has focused on the new treatment options for AGC. In the last two decades, many targeted molecules were developed against AGC. Currently, two targeted therapy molecules have been approved for patients with AGC. In 2010, trastuzumab was the first molecule shown to improve survival in patients with HER2-positive AGC as part of a first-line combination regimen. In 2014, ramucirumab was the second targeted molecule to improve survival rates and was suggested as treatment for patients with AGC who had progressed after first-line platinum plus fluoropyrimidine with or without anthracycline chemotherapy. Ramucirumab was the first targeted therapy acting as a single agent in patients with advanced gastroesophageal cancers. Although these two molecules were introduced into clinical use, many other promising molecules have been tested in phase I - II trials. It is obvious that in the near future many different targeted therapies will be in use for treatment of AGC. In this review, the current status of targeted therapies in the treatment of AGC and gastroesophageal junction tumors, including HER (2-3) inhibitors, epidermal growth factor receptor inhibitors, tyrosine kinase inhibitors, antiangiogenic agents, c-MET inhibitors, mammalian target of rapamycin inhibitors, agents against other molecular pathways fibroblast growth factor, Claudins, insulin-like growth factor, heat shock proteins, and immunotherapy, will be discussed.
URI
https://doi.org/10.3748/wjg.v22.i2.471
http://hdl.handle.net/11655/22218
xmlui.mirage2.itemSummaryView.Collections
  • Kanser Enstitüsü Makale Koleksiyonu [40]
Hacettepe Üniversitesi Kütüphaneleri
Açık Erişim Birimi
Beytepe Kütüphanesi | Tel: (90 - 312) 297 6585-117 || Sağlık Bilimleri Kütüphanesi | Tel: (90 - 312) 305 1067
Bizi Takip Edebilirsiniz: Facebook | Twitter | Youtube | Instagram
Web sayfası:www.library.hacettepe.edu.tr | E-posta:openaccess@hacettepe.edu.tr
Sayfanın çıktısını almak için lütfen tıklayınız.
Contact Us | Send Feedback



DSpace software copyright © 2002-2016  DuraSpace
Theme by 
Atmire NV
 

 


DSpace@Hacettepe
huk openaire onayı
by OpenAIRE

About HUAES
Open Access PolicyGuidesSubcriptionsContact

livechat

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherLanguageRightsIndexing SourceFundingxmlui.ArtifactBrowser.Navigation.browse_subtypeThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherLanguageRightsIndexing SourceFundingxmlui.ArtifactBrowser.Navigation.browse_subtype

My Account

LoginRegister

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Theme by 
Atmire NV